Fintel reports that on January 20, 2026, Canaccord Genuity upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from Hold to Buy.
Analyst Price Forecast Suggests 65.89% Upside
As of January 13, 2026, the average one-year price target for BioMarin Pharmaceutical is $93.43/share. The forecasts range from a low of $60.60 to a high of $128.10. The average price target represents an increase of 65.89% from its latest reported closing price of $56.32 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for BioMarin Pharmaceutical is 4,031MM, an increase of 30.28%. The projected annual non-GAAP EPS is 18.00.
What is the Fund Sentiment?
There are 1,085 funds or institutions reporting positions in BioMarin Pharmaceutical. This is an decrease of 67 owner(s) or 5.82% in the last quarter. Average portfolio weight of all funds dedicated to BMRN is 0.21%, an increase of 0.42%. Total shares owned by institutions decreased in the last three months by 6.14% to 220,602K shares. 
The put/call ratio of BMRN is 0.44, indicating a bullish outlook.
What are Other Shareholders Doing?
Primecap Management holds 15,229K shares representing 7.93% ownership of the company. In its prior filing, the firm reported owning 15,772K shares , representing a decrease of 3.56%. The firm decreased its portfolio allocation in BMRN by 8.06% over the last quarter.
Dodge & Cox holds 14,687K shares representing 7.64% ownership of the company. In its prior filing, the firm reported owning 15,108K shares , representing a decrease of 2.87%. The firm decreased its portfolio allocation in BMRN by 8.03% over the last quarter.
DODGX - Dodge & Cox Stock Fund holds 9,770K shares representing 5.09% ownership of the company. No change in the last quarter.
Viking Global Investors holds 8,322K shares representing 4.33% ownership of the company. In its prior filing, the firm reported owning 12,289K shares , representing a decrease of 47.66%. The firm decreased its portfolio allocation in BMRN by 40.06% over the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 6,247K shares representing 3.25% ownership of the company. In its prior filing, the firm reported owning 6,214K shares , representing an increase of 0.52%. The firm decreased its portfolio allocation in BMRN by 26.30% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
